Evidence map›Paper›PMID 21801395›Full record

ArticleInfectious agents and cancer2011

A population-based cross-sectional study of age-specific risk factors for high risk human papillomavirus prevalence in rural Nigeria.

Megan A Clarke, Julia C Gage, Kayode O Ajenifuja, Nicolas A Wentzensen, Akinfolarin C Adepiti, Sholom Wacholder, Robert D Burk, Mark Schiffman

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Infectious agents and cancer, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00804466 (Epidemiologic and Molecular Features of Cervical Cancer in Nigeria - Project Itoju), which is not on this map. Cited by 18 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 3 pooled it
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00804466 nacompletednot on this map

Epidemiologic and Molecular Features of Cervical Cancer in Nigeria - Project Itoju (Care)

TypeinterventionalSponsorNational Cancer Institute (NCI)Ran2009 to 2020Enrolled1,466ConditionsHuman Papillomavirus 18, Cervical Intraepithelial Neoplasia, Human Papillomavirus 16, Uterine Cervical NeoplasmsArmsOncoE6, EVA System
3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 3 syntheses or guidelines pooled it, 28 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 2 countries.

Megan A ClarkeDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, DHHS, Bethesda, MD, USA. clarkma2@mail.nih.gov.
Julia C Gage
Kayode O Ajenifuja
Nicolas A Wentzensen
Akinfolarin C Adepiti
Sholom Wacholder
Robert D Burk
Mark Schiffman
National Institutes of Health · USObafemi Awolowo University · NGUnited States Department of Health and Human Services · USAlbert Einstein College of Medicine · USNational Cancer Institute · US

Funding

Human Papillomavirus (HPV) Natural History, Genomics and Risk AssessmentZIACP010206 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI SCHIFFMAN, MARK · 2010 to 2025
$17.1M
PERSISTENT HUMAN PAPILLOMAVIRUS IN WOMEN AT RISK FOR CERVIX CANCERU01CA078527 · NCI · YESHIVA UNIVERSITY · PI BURK, ROBERT D · 2003 to 2018
$8.6M
PERSISTENT HPV IN WOMEN AT RISK FOR CERVIX CANCERR01CA078527 · NCI · YESHIVA UNIVERSITY · PI BURK, ROBERT D. · 1998 to 2002
$1.5M
NCI NIH HHS R01 CA078527NCI NIH HHS U01 CA078527
6 · The paper itself

Abstract

backgroundCervical cancer, caused by persistent infection with carcinogenic human papillomavirus (HR-HPV), is particularly prevalent in Sub-Saharan Africa and is associated with a high mortality rate. Some studies in West Africa, including our own, have found unusually high HR-HPV across all ages with a slight peak in older women. This increased prevalence at older ages may complicate screen-and-treat programs, which are implemented in regions where HPV prevalence declines with age and typically target women between 30-49 years. A better understanding of the determinants of high HR-HPV prevalence at older ages is needed. The goal of this study is to explore risk factors for HR-HPV prevalence by age among women in our population-based study in Irun, a rural town in southwestern Nigeria.

methods1,420 women were administered a clinic-based questionnaire regarding sexual and reproductive behavior, marital status (including co-wives), and malaria exposure. Logistic regression compared questionnaire responses and PCR positivity for a set of 13 carcinogenic HR-HPV types. Results were stratified by age (15-29, 30-45, 46-55, and 56+ years).

resultsBirth control use and age at first pregnancy were associated with HR-HPV (p-value = 0.03 and 0.05, respectively). Early age at sexual debut and multiple sex partners were risks for HR-HPV, but did not reach significance (p-value = 0.1 and 0.07, respectively). Neither self-reported malaria nor presence of co-wives in the household was associated with HR-HPV (p-value = 0.85 and 0.24, respectively). In age sub-categories, early age at sexual debut was a significant risk factor for HR-HPV among women 35-45 years (p-value = 0.02). Early age at first pregnancy remained a significant risk factor for women aged 56+ years (p-value = 0.04). Greater than 2 sex partners and use of birth control were associated (though not significantly) with HR-HPV in women aged 30-45 (p-value = 0.08, respectively).

conclusionsIn this high-risk region with elevated HR-HPV prevalence at older ages, we confirmed previously described, behavioral determinants of HR-HPV. There was no association with self-reported malaria or co-wives, which we had hypothesized might correlate with HR-HPV at older ages.

Identifiers

PMID21801395
PMCPMC3162906
OpenAlexW2126075246

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.